Below is a roundup of payer-centric news headlines you may have missed during the month of October 2024
Plaintiffs allege that internal testing for semaglutide suggested a slowing of gastric emptying, yet clinical labeling for the general public did not adequately convey the extent of the risk involving permanent stomach dysfunction
[DOI] [PubMed] [Google Scholar] 19.Nreu B, Dicembrini I, Tinti F, Sesti G, Mannucci E, et al
One of the main reasons Ozempic and other GLP-1 agonist medications are so effective is because they target your brain, not just your stomach
Foundational Support for Cellular and Whole-Body Wellness Every day, your body relies on glutathione to help maintain antioxidant balance while supporting natural detoxification and immune function
Advertisements often focus on highlighting only the positive aspects of a product, which can make it even more confusing